Schroder Investment Management Group Boosts Stake in Masimo Corporation $MASI

Schroder Investment Management Group grew its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 3.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 448,501 shares of the medical equipment provider’s stock after acquiring an additional 12,953 shares during the period. Schroder Investment Management Group owned about 0.83% of Masimo worth $75,447,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Masimo by 5.0% during the 2nd quarter. Assetmark Inc. now owns 1,539 shares of the medical equipment provider’s stock valued at $259,000 after buying an additional 73 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Masimo by 1.5% during the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after buying an additional 92 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Masimo by 5.3% in the second quarter. ProShare Advisors LLC now owns 1,995 shares of the medical equipment provider’s stock worth $336,000 after buying an additional 101 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Masimo by 2.9% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,039 shares of the medical equipment provider’s stock worth $673,000 after buying an additional 115 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MASI has been the topic of several recent analyst reports. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Piper Sandler upped their target price on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Bank of America initiated coverage on shares of Masimo in a research report on Monday, November 17th. They set a “neutral” rating and a $162.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $198.00 price target on shares of Masimo in a research note on Monday, November 24th. Finally, Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Masimo has a consensus rating of “Hold” and a consensus price target of $188.40.

Masimo Trading Down 1.0%

NASDAQ MASI opened at $142.57 on Friday. The firm has a market capitalization of $7.66 billion, a PE ratio of -16.73 and a beta of 1.28. Masimo Corporation has a one year low of $133.70 and a one year high of $194.88. The company has a 50-day simple moving average of $145.77 and a 200-day simple moving average of $152.31. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14.

Masimo (NASDAQ:MASI) last issued its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. The firm had revenue of $617.00 million for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. On average, equities analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.